

ISOPTO CARPINE- pilocarpine hydrochloride solution/ drops
Alcon Laboratories, Inc.

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ISOPTO CARPINE safely and effectively. See full prescribing information for ISOPTO CARPINE.

ISOPTO® CARPINE (pilocarpine hydrochloride ophthalmic solution)
Initial U.S. Approval: 1974

----- **INDICATIONS AND USAGE** -----

Isopto Carpine is a muscarinic cholinergic agonist indicated for:

- The reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. (1.1)
- The management of acute angle-closure glaucoma. (1.2)
- The prevention of postoperative elevated IOP associated with laser surgery. (1.3)
- The induction of miosis. (1.4)

----- **DOSAGE AND ADMINISTRATION** -----

- Instill one drop in the eye(s) up to four times daily. (2)

----- **DOSAGE FORMS AND STRENGTHS** -----

- Solution containing 1% (10 mg/mL), 2% (20 mg/mL) or 4% (40 mg/mL) pilocarpine hydrochloride. (3)

----- **CONTRAINDICATIONS** -----

None. (4)

----- **WARNINGS AND PRECAUTIONS** -----

- Poor Illumination: Exercise caution in night driving and other hazardous occupations in poor illumination. (5.1)
- Preexisting Retinal Disease: Rare cases of retinal detachment have been reported; a thorough examination of the retina, including funduscopy is advised in all patients prior to the initiation of therapy. (5.2)
- Iritis: Caution is advised in patients with iritis. (5.3)
- Congenital Glaucoma: Caution is advised in pediatric patients with primary congenital glaucoma for control of IOP as cases of a paradoxical increase in IOP have been reported. (5.4)

----- **ADVERSE REACTIONS** -----

Most common adverse reactions are headache/browache, accommodative change, eye irritation, eye pain, blurred vision, and/or visual impairment. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 5/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

- 1.1 Reduction of Elevated Intraocular Pressure (IOP) in Patients With Open-Angle Glaucoma or Ocular Hypertension
- 1.2 Management of Acute Angle-Closure Glaucoma
- 1.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery
- 1.4 Induction of Miosis

2 DOSAGE AND ADMINISTRATION

- 2.1 Reduction of Elevated IOP in Patients With Open-Angle Glaucoma or Ocular Hypertension
- 2.2 Management of Acute Angle-Closure Glaucoma

2.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery

2.4 Induction of Miosis

2.5 Use With Other Topical Ophthalmic Medications

2.6 Use in Pediatric Patients

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Poor Illumination

5.2 Preexisting Retinal Disease

5.3 Iritis

5.4 Primary Congenital Glaucoma

5.5 Contact Lens Wear

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

Isopto[®] Carpine is indicated for the:

1.1 Reduction of Elevated Intraocular Pressure (IOP) in Patients With Open-Angle Glaucoma or Ocular Hypertension

1.2 Management of Acute Angle-Closure Glaucoma

1.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery

1.4 Induction of Miosis

2 DOSAGE AND ADMINISTRATION

2.1 Reduction of Elevated IOP in Patients With Open-Angle Glaucoma or Ocular Hypertension

One drop of Isopto[®] Carpine 1%, 2%, or 4% should be applied topically in the eye(s) up to four times daily. Pilocarpine-naïve patients should be started on the 1% concentration as higher concentrations are often not tolerated initially. The frequency of instillation and concentration of Isopto[®] Carpine are determined by the severity of the elevated intraocular pressure and miotic response of the patient.

To limit systemic exposure to pilocarpine, patients may be instructed to perform punctal occlusion for 2 minutes after instillation of Isopto[®] Carpine ophthalmic solution.

2.2 Management of Acute Angle-Closure Glaucoma

Prior to Isopto[®] Carpine use, treatment with secretory suppressants and hyperosmotic agents may be needed to lower IOP below 50 mmHg and relieve iris ischemia. For initial management of acute angle-closure glaucoma, one drop of Isopto[®] Carpine 1% or 2% may be applied topically in the eye(s) up to three times over a 30-minute period.

If laser iridoplasty or iridomy is used to break the attack, one drop of Isopto[®] Carpine 4% should be administered prior to the procedure. Following laser iridoplasty, one drop of Isopto[®] Carpine 1% should be administered four times daily until an iridotomy can be performed.

2.3 Prevention of Postoperative Elevated IOP Associated With Laser Surgery

One drop of Isopto[®] Carpine 1%, 2%, or 4% (or two drops administered five minutes apart) should be applied topically in the eye(s) 15 to 60 minutes prior to surgery.

2.4 Induction of Miosis

One drop of Isopto[®] Carpine 1%, 2%, or 4% (or two drops administered five minutes apart) should be applied topically in the eye(s).

2.5 Use With Other Topical Ophthalmic Medications

Isopto[®] Carpine may be used in combination with beta-blockers, carbonic anhydrase inhibitors, sympathomimetics or hyperosmotic agents. If more than one topical ophthalmic drug is being used, the drugs should be administered at least five minutes apart.

2.6 Use in Pediatric Patients

In children under 2 years of age, one drop of Isopto[®] Carpine 1% should be applied topically in the eye(s) three times daily. Children 2 years of age and over should be dosed as for adults. For the induction of miosis prior to goniotomy or trabeculotomy in children, one drop of Isopto[®] Carpine 1% or 2% should be applied topically in the eye 15 to 60 minutes prior to surgery.

3 DOSAGE FORMS AND STRENGTHS

Bottle filled with 15 mL of 1% (10 mg/mL), 2% (20 mg/mL), or 4% (40 mg/mL) pilocarpine hydrochloride sterile ophthalmic solution.

4 CONTRAINDICATIONS

None.

5 WARNINGS AND PRECAUTIONS

5.1 Poor Illumination

Patients should be advised to exercise caution in night driving and other hazardous occupations in poor illumination. In addition, miotics may cause accommodative spasm. Patients should be advised not to drive or use machinery if vision is not clear.

5.2 Preexisting Retinal Disease

As with all miotics, rare cases of retinal detachment have been reported when used in certain susceptible individuals and those with preexisting retinal disease; therefore, a thorough examination of the retina including funduscopy is advised in all patients prior to the initiation of therapy.

5.3 Iritis

Isopto[®] Carpine is not recommended to be used when iritis is present.

5.4 Primary Congenital Glaucoma

Caution is advised when using Isopto[®] Carpine in pediatric patients with primary congenital glaucoma for control of IOP as cases of a paradoxical increase in IOP have been reported. In addition, the use of Isopto[®] Carpine is not recommended in pediatric patients diagnosed with glaucoma secondary to anterior segment dysgenesis or uveitis (especially if uveitis is active).

5.5 Contact Lens Wear

Contact lens wearers should be advised to remove their lenses prior to the instillation of Isopto[®] Carpine ophthalmic solution and to wait 10 minutes after dosing before reinserting their contact lenses.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety data described below reflect exposure in four controlled clinical trials of 90 days to 2 years duration in 317 patients diagnosed with open-angle glaucoma or ocular hypertension. In the four clinical trials, patients were treated with Isopto[®] Carpine 2%, two to four times daily or with pilocarpine 1%, 1.75%, or 2% in fixed combination with betaxolol 0.25%, two or three times daily. The most frequently reported adverse reactions occurring in $\geq 5\%$ of patients in the pilocarpine 2% populations were: headache/brow ache, accommodative change, blurred vision, eye irritation, visual impairment (dim, dark, or “jumping” vision), and eye pain.

The adverse reaction profile reported for the use of Isopto[®] Carpine in pediatric patients is comparable to that seen in adult patients.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy. Category C. Animal reproduction studies have not been conducted with pilocarpine hydrochloride. It is also not known whether pilocarpine hydrochloride can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Isopto[®] Carpine should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Isopto[®] Carpine is administered to a nursing woman.

8.4 Pediatric Use

Safety and effectiveness of pilocarpine hydrochloride ophthalmic solution in pediatric patients have been established.

8.5 Geriatric Use


No overall differences in safety or effectiveness have been observed between elderly and younger patients.

10 OVERDOSAGE

Systemic toxicity following topical ocular administration of pilocarpine is rare, but occasionally patients who are sensitive may develop sweating and gastrointestinal overactivity following the suggested dosage and administration. Overdosage can produce sweating, salivation, nausea, tremors and slowing of the pulse and a decrease in blood pressure. In moderate overdosage, spontaneous recovery is to be expected and is aided by intravenous fluids to compensate for dehydration. For patients demonstrating severe poisoning, atropine, the pharmacologic antagonist to pilocarpine, should be used.

11 DESCRIPTION

Isopto[®] Carpine (pilocarpine hydrochloride ophthalmic solution) is a cholinergic agonist prepared as a sterile topical ophthalmic solution. The active ingredient is represented by the chemical structure:



Established name: pilocarpine hydrochloride

Chemical name: 2(3*H*)-furanone, 3-ethylidihydro-4-[(1-methyl-1*H*-imidazol-5-yl)-methyl]-monohydrochloride, (3*S*-*cis*)-. Molecular Formula: C₁₁H₁₆N₂O₂ • HCl; Molecular Weight: 244.72 g/mol.

Each mL of Isopto[®] Carpine (pilocarpine hydrochloride ophthalmic solution) contains:

Active: pilocarpine hydrochloride 1% (10 mg/mL), 2% (20 mg/mL), or 4% (40 mg/mL).

Preservative: benzalkonium chloride 0.01%.

Inactives: hypromellose 2910, boric acid, sodium citrate, sodium chloride (present in 1% only); hydrochloric acid and/or sodium hydroxide (to adjust pH); purified water. Isopto[®] Carpine has a pH of 3.5 to 5.5 and an osmolality of 290 to 350 mOsm/kg (1% and 2% products) and 550 to 600 mOsm/kg (4% product).

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Pilocarpine hydrochloride is a direct acting cholinergic parasympathomimetic agent which acts through direct stimulation of muscarinic receptors and smooth muscle such as the iris and secretory glands. Pilocarpine contracts the ciliary muscle, causing increased tension on the scleral spur and opening of the trabecular meshwork spaces to facilitate outflow of aqueous humor. Outflow resistance is reduced, lowering IOP. Pilocarpine also produces miosis through contraction of the iris sphincter muscle. Miosis relieves appositional angle narrowing and closure, which lowers IOP in certain types of angle-closure glaucoma.

12.3 Pharmacokinetics

Systemic exposure to pilocarpine was evaluated in 14 healthy subjects administered 2 drops of Isopto[®] Carpine (pilocarpine hydrochloride ophthalmic solution) 4% to both eyes four times daily for eight days. A comparison of C_{max} values on Days 5 and 8 indicated that pilocarpine concentrations in plasma reached steady-state following topical administration of Isopto[®] Carpine 4%. The mean (SD) C_{max} and AUC_{0-last} values on Day 8 were 3.7 (3.2) ng/mL and 7.7 (8.4) ng×hour/mL, respectively. The T_{max} values on Day 8 ranged from 0.5 to 1 hour.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

There have been no long-term studies done using pilocarpine hydrochloride in animals to evaluate carcinogenic potential.

14 CLINICAL STUDIES

In clinical trials reported in the medical literature, pilocarpine ophthalmic solution reduced IOP by 3-7 mmHg in patients with open-angle glaucoma. Pilocarpine ophthalmic solution has also been shown to be effective in the induction of miosis, in the prevention of postoperative elevated IOP, and in the management of acute angle-closure glaucoma.

16 HOW SUPPLIED/STORAGE AND HANDLING

Isopto[®] Carpine (pilocarpine hydrochloride ophthalmic solution) 1%, 2%, and 4% is supplied sterile in natural low density polyethylene plastic ophthalmic dispensers and green low density polyethylene tips with green polypropylene caps.

15 mL in 15 mL bottles

1%: NDC 0998-0203-15

2%: NDC 0998-0204-15

4%: NDC 0998-0206-15

STORAGE: Store at 20°C to 25°C (68° to 77°F), excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from freezing.

17 PATIENT COUNSELING INFORMATION

Avoiding Contamination of the Product

Do not touch dropper tip to any surface, as this may contaminate the contents.

Night Driving

Caution is advised with night driving and when hazardous activities are undertaken in poor illumination.

Accommodative Spasm

Isopto[®] Carpine ophthalmic solution may cause problems when changing focus between near objects and distant objects. Do not drive or use machinery if vision is not clear.

Contact Lens Wear

Contact lens should be removed prior to the instillation of Isopto[®] Carpine ophthalmic solution. Wait 10 minutes after dosing before reinserting contact lenses.

Concomitant Topical Ocular Therapy

If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.

Systemic Exposure

To limit exposure to pilocarpine to the eye alone, close eyes gently and apply pressure with finger to the corner of eye by the nose for 2 minutes after instillation of Isopto[®] Carpine ophthalmic solution.

Distributed by:

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936

© Novartis

T2020-78

PRINCIPAL DISPLAY PANEL

NDC 0998-0203-15

Alcon[®]

Isopto[®]

Carpine 1%

(pilocarpine hydrochloride ophthalmic solution)

15 mL Sterile

Rx Only



PRINCIPAL DISPLAY PANEL

NDC 0998-0204-15

Alcon®

Isopto®
Carpine 2%
(pilocarpine hydrochloride ophthalmic solution)

15 mL Sterile

Rx Only



PRINCIPAL DISPLAY PANEL


NDC 0998-0206-15

Alcon®

Isopto®
Carpine 4%
(pilocarpine hydrochloride ophthalmic solution)

15 mL Sterile

Rx Only



ISOPTO CARPINE

pilocarpine hydrochloride solution/ drops

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0998-0203
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
PILOCARPINE HYDROCHLORIDE (UNII: 0 WW6 D218 XJ) (PILOCARPINE - UNII:01MI4Q9D13)	PILOCARPINE HYDROCHLORIDE	10 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)	
HYPROMELLOSE 2910 (15 MPA.S) (UNII: 36SFW2JZ0W)	
BORIC ACID (UNII: R57ZHV85D4)	
SODIUM CITRATE (UNII: 1Q73Q2JULR)	
SODIUM CHLORIDE (UNII: 451W47IQ8X)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0998-0203-15	1 in 1 CARTON	01/01/1974	
1		15 mL in 1 BOTTLE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA200890	01/01/1974	

ISOPTO CARPINE

pilocarpine hydrochloride solution/ drops

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0998-0204
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
PILOCARPINE HYDROCHLORIDE (UNII: 0WW6D218XJ) (PILOCARPINE - UNII:01MI4Q9DI3)	PILOCARPINE HYDROCHLORIDE	20 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)	
HYPROMELLOSE 2910 (15 MPA.S) (UNII: 36SFW2JZ0W)	
BORIC ACID (UNII: R57ZHV85D4)	
SODIUM CITRATE (UNII: 1Q73Q2JULR)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0998-0204-15	1 in 1 CARTON	01/01/1974	
1		15 mL in 1 BOTTLE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA200890	01/01/1974	

ISOPTO CARPINE

pilocarpine hydrochloride solution/ drops

Product Information

Product Type	HUMAN PRESCRIPTION DRUG	Item Code (Source)	NDC:0998-0206
Route of Administration	OPHTHALMIC		

Active Ingredient/Active Moiety

Ingredient Name	Basis of Strength	Strength
PILOCARPINE HYDROCHLORIDE (UNII: 0WW6D218XJ) (PILOCARPINE - UNII:01MI4Q9DI3)	PILOCARPINE HYDROCHLORIDE	40 mg in 1 mL

Inactive Ingredients

Ingredient Name	Strength
BENZALKONIUM CHLORIDE (UNII: F5UM2KM3W7)	
HYPROMELLOSE 2910 (15 MPA.S) (UNII: 36SFW2JZ0W)	
BORIC ACID (UNII: R57ZHV85D4)	
SODIUM CITRATE (UNII: 1Q73Q2JULR)	
HYDROCHLORIC ACID (UNII: QTT17582CB)	
SODIUM HYDROXIDE (UNII: 55X04QC32I)	
WATER (UNII: 059QF0KO0R)	

Packaging

#	Item Code	Package Description	Marketing Start Date	Marketing End Date
1	NDC:0998-0206-15	1 in 1 CARTON	01/01/1974	
1		15 mL in 1 BOTTLE; Type 0: Not a Combination Product		

Marketing Information

Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA200890	01/01/1974	

Labeler - Alcon Laboratories, Inc. (008018525)

Revised: 5/2020

Alcon Laboratories, Inc.